[en] BackgroundMultiple Endocrine Neoplasia syndrome type 1 (MEN1), which is secondary to mutation of the MEN1 gene, is a rare autosomal-dominant disease that predisposes mutation carriers to endocrine tumors. Although genotype-phenotype studies have so far failed to identify any statistical correlations, some families harbor recurrent tumor patterns. The function of MENIN is unclear but has been described through the discovery of its interacting partners. Mutations in the interacting domains of MENIN functional partners have been shown to directly alter its regulation abilities.MethodsWe report on a cohort of MEN1 patients from the Groupe d'etude des Tumeurs Endocrines. Patients with a molecular diagnosis and a clinical follow-up, totalling 262 families and 806 patients were included. Associations between mutation type, location or interacting factors of the MENIN protein and death as well as the occurrence of MEN1-related tumors were tested using a frailty Cox model to adjust for potential heterogeneity across families.ResultsAccounting for the heterogeneity across families, the overall risk of death was significantly higher when mutations affected the JunD interacting domain (adjusted HR=1.88: 95%-CI=1.15- 3.07). Patients had a higher risk of death from cancers of the MEN1 spectrum (HR=2.34; 95%-CI=1.23- 4.43).ConclusionThis genotype-phenotype correlation study confirmed the lack of direct genotype-phenotype correlations. However, patients with mutations affecting the JunD interacting domain had a higher risk of death secondary to a MEN1 tumor and should thus be considered for surgical indications, genetic counseling and follow-up.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Thevenon, Julien
Bourredjem, Abderrahmane
Faivre, Laurence
Cardot-Bauters, Catherine
Calender, Alain
Murat, Arnaud
Giraud, Sophie
Niccoli, Patricia
Odou, Marie-Francoise
Borson-Chazot, Francoise
Barlier, Anne
Lombard-Bohas, Catherine
Clauser, Eric
Tabarin, Antoine
Parfait, Beatrice
Chabre, Olivier
CASTERMANS, Emilie ; Centre Hospitalier Universitaire de Liège - CHU > Génétique
BECKERS, Albert ; Centre Hospitalier Universitaire de Liège - CHU > Endocrinologie clinique
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Wermer, P. (1968) Duality of pancreatogenous peptic ulcer. N. Engl. J. Med., 278, 397-398.
Kouvaraki, M.A., Lee, J.E., Shapiro, S.E., Gagel, R.F., Sherman, S.I., Sellin, R.V., Cote, G.J. and Evans, D.B. (2002) Genotype-phenotype analysis in multiple endocrine neoplasia type 1. Arch. Surg., 137, 641-647.
Teh, B.T., McArdle, J., Chan, S.P., Menon, J., Hartley, L., Pullan, P., Ho, J., Khir, A., Wilkinson, S., Larsson, C. et al. (1997) Clinicopathologic studies of thymic carcinoids in multiple endocrine neoplasia type 1. Medicine (Baltimore), 76, 21-29.
Guru, S.C., Manickam, P., Crabtree, J.S., Olufemi, S.E., Agarwal, S.K. and Debelenko, L.V. (1998) Identification and characterization of the multiple endocrine neoplasia type 1 (MEN1) gene. J. Intern. Med., 243, 433-439.
Guru, S.C., Goldsmith, P.K., Burns, A.L., Marx, S.J., Spiegel, A.M., Collins, F.S. and Chandrasekharappa, S.C. (1998) Menin, the product of the MEN1 gene, is a nuclear protein. Proc. Natl. Acad. Sci. USA, 95, 1630-1634.
Wautot, V., Vercherat, C., Lespinasse, J., Chambe, B., Lenoir, G.M., Zhang, C.X., Porchet, N., Cordier, M., Beroud, C. and Calender, A. (2002) Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: search for correlation between phenotype and the functional domains of the MEN1 protein. Hum. Mutat., 20, 35-47.
Chandrasekharappa, S.C. and Teh, B.T. (2001) Clinical and molecular aspects of multiple endocrine neoplasia type 1. Front. Horm. Res., 28, 50-80.
Lemos, M.C. and Thakker, R.V. (2008) Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum. Mutat., 29, 22-32.
Faivre, L., Collod-Beroud, G., Loeys, B.L., Child, A., Binquet, C., Gautier, E., Callewaert, B., Arbustini, E., Mayer, K., Arslan-Kirchner, M. et al. (2007) Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. Am. J. Hum. Genet., 81, 454-466.
Margraf, R.L., Crockett, D.K., Krautscheid, P.M., Seamons, R., Calderon, F.R., Wittwer, C.T. and Mao, R. (2009) Multiple endocrine neoplasia type 2 RET protooncogene database: repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations. Hum. Mutat., 30, 548-556.
Lips, C.J., Dreijerink, K.M. and Hoppener, J.W. (2012) Variable clinical expression in patients with a germline MEN1 disease gene mutation: clues to a genotype-phenotype correlation. Clinics, 67, 49-56.
Marini, F., Falchetti, A., Luzi, E., Tonelli, F. and Maria Luisa, B. (2009) Multiple Endocrine Neoplasia Type 1 (MEN1) Syndrome. Cancer Syndromes. Bethesda, MD, National Center for Biotechnology Information (US).
Taal, B.G. and Visser, O. (2004) Epidemiology of neuroendocrine tumours. Neuroendocrinology, 80, 3-7.
Tonelli, F., Giudici, F., Fratini, G. and Brandi, M.L. (0000) Pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: review of literature. Endocr. Pract., 17, 33-40.
Goudet, P., Murat, A., Binquet, C., Cardot-Bauters, C., Costa, A., Ruszniewski, P., Niccoli, P., Menegaux, F., Chabrier, G., Borson-Chazot, F. et al. (2010) Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. World J. Surg., 34, 249-255.
Levy-Bohbot, N., Merle, C., Goudet, P., Delemer, B., Calender, A., Jolly, D., Thiefin, G. and Cadiot, G. (2004) Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol. Clin. Biol., 28, 1075-1081.
Triponez, F., Dosseh, D., Goudet, P., Cougard, P., Bauters, C., Murat, A., Cadiot, G., Niccoli-Sire, P., Chayvialle, J.A., Calender, A. et al. (2006) Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann. Surg., 243, 265-272.
Verges, B., Boureille, F., Goudet, P., Murat, A., Beckers, A., Sassolas, G., Cougard, P., Chambe, B., Montvernay, C. and Calender, A. (2002) Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J. Clin. Endocrinol. Metab., 87, 457-465.
Goudet, P., Murat, A., Cardot-Bauters, C., Emy, P., Baudin, E., du Boullay Choplin, H., Chapuis, Y., Kraimps, J.L., Sadoul, J.L., Tabarin, A. et al. (2009) Thymic neuroendocrine tumors in multiple endocrine neoplasia type 1: a comparative study on 21 cases among a series of 761 MEN1 from the GTE (Groupe des Tumeurs Endocrines). World J. Surg., 33, 1197-1207.
Goudet, P., Bonithon-Kopp, C., Murat, A., Ruszniewski, P., Niccoli, P., Menegaux, F., Chabrier, G., Borson-Chazot, F., Tabarin, A., Bouchard, P. et al. (0000) Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d'etude des Tumeurs Endocrines. Eur. J. Endocrinol., 165, 97-105.
Sakurai, A., Suzuki, S., Kosugi, S., Okamoto, T., Uchino, S., Miya, A., Imai, T., Kaji, H., Komoto, I., Miura, D. et al. (0000) Multiple endocrine neoplasia type 1 in Japan: establishment and analysis of a multicentre database. Clin. Endocrinol. (Oxf.), 76, 533-539.
Machens, A., Schaaf, L., Karges, W., Frank-Raue, K., Bartsch, D.K., Rothmund, M., Schneyer, U., Goretzki, P., Raue, F. and Dralle, H. (2007) Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clin. Endocrinol. (Oxf.), 67, 613-622.
Agarwal, S.K., Guru, S.C., Heppner, C., Erdos, M.R., Collins, R.M., Park, S.Y., Saggar, S., Chandrasekharappa, S.C., Collins, F.S., Spiegel, A.M. et al. (1999) Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell, 96, 143-152.
Agarwal, S.K., Kennedy, P.A., Scacheri, P.C., Novotny, E.A., Hickman, A.B., Cerrato, A., Rice, T.S., Moore, J.B., Rao, S., Ji, Y. et al. (2005) Menin molecular interactions: insights into normal functions and tumorigenesis. Horm. Metab. Res., 37, 369-374.
Agarwal, S.K., Novotny, E.A., Crabtree, J.S., Weitzman, J.B., Yaniv, M., Burns, A.L., Chandrasekharappa, S.C., Collins, F.S., Spiegel, A.M. and Marx, S.J. (2003) Transcription factor JunD, deprived of menin, switches from growth suppressor to growth promoter. Proc. Natl. Acad. Sci. USA, 100, 10770-10775.
Knapp, J.I., Heppner, C., Hickman, A.B., Burns, A.L., Chandrasekharappa, S.C., Collins, F.S., Marx, S.J., Spiegel, A.M. and Agarwal, S.K. (2000) Identification and characterization of JunD missense mutants that lack menin binding. Oncogene, 19, 4706-4712.
Shimazu, S., Nagamura, Y., Yaguchi, H., Ohkura, N. and Tsukada, T. (2011) Correlation of mutant menin stability with clinical expression of multiple endocrine neoplasia type 1 and its incomplete forms. Cancer Sci., 102, 2097-2102.
Goudet, P., Cougard, P., Verges, B., Murat, A., Carnaille, B., Calender, A., Faivre, J. and Proye, C. (2001) Hyperparathyroidism in multiple endocrine neoplasia type I: surgical trends and results of a 256-patient series from Groupe D'etude des Neoplasies Endocriniennes Multiples Study Group. World J. Surg., 25, 886-890.
Giraud, S., Zhang, C.X., Serova-Sinilnikova, O., Wautot, V., Salandre, J., Buisson, N., Waterlot, C., Bauters, C., Porchet, N., Aubert, J.P. et al. (1998) Germ-line mutation analysis in patients with multiple endocrine neoplasia type 1 and related disorders. Am. J. Hum. Genet., 63, 455-467.
Calender, A. (2010) Multiple endocrine neoplasia: genetic aspects. Bull. Acad. Natl. Med., 194, 81-95.
Gatta-Cherifi, B., Chabre, O., Murat, A., Niccoli, P., Cardot-Bauters, C., Rohmer, V., Young, J., Delemer, B., Du Boullay, H., Verger, M.F. et al. (0000) Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d'etude des Tumeurs Endocrines database. Eur. J. Endocrinol., 166, 269-279.
Triponez, F., Goudet, P., Dosseh, D., Cougard, P., Bauters, C., Murat, A., Cadiot, G., Niccoli-Sire, P., Calender, A. and Proye, C.A. (2006) Is surgery beneficial for MEN1 patients with small (< or =2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J. Surg., 30, 654-662.
Green, G.H. and Diggle, P.J. (2007) On the operational characteristics of the Benjamini and Hochberg false discovery rate procedure. Stat. Appl. Genet. Mol. Biol., 6, 27.
Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N. and Golani, I. (2001) Controlling the false discovery rate in behavior genetics research. Behav. Brain Res., 125, 279-284.
Benjamini, Y. and Hochberg, Y. (1995) Controlling the false discovery rate - a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Methodol., 57, 289-300.
Teh, B.T. (1998) Thymic carcinoids in multiple endocrine neoplasia type1. J. Intern. Med., 243, 501-504.
Huang, J., Gurung, B., Wan, B., Matkar, S., Veniaminova, N.A., Wan, K., Merchant, J.L., Hua, X. and Lei, M. (2012) The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature, 482, 542-546.
Grembecka, J., He, S., Shi, A., Purohit, T., Muntean, A.G., Sorenson, R.J., Showalter, H.D., Murai, M.J., Belcher, A.M., Hartley, T. et al. (0000) Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat. Chem. Biol., 8, 277-284.
Zerbini, L.F., de Vasconcellos, J.F., Czibere, A., Wang, Y., Paccez, J.D., Gu, X., Zhou, J.R. and Libermann, T.A. (2011) JunD-mediated repression of GADD45alpha and gamma regulates escape from cell death in prostate cancer. Cell Cycle, 10, 2583-2591.
Chen, D., Reierstad, S., Fang, F. and Bulun, S.E. (2011) JunD and JunB integrate prostaglandin E2 activation of breast cancer-associated proximal aromatase promoters. Mol. Endocrinol., 25, 767-775.
Dreijerink, K.M., Hoppener, J.W., Timmers, H.M. and Lips, C.J. (2006) Mechanisms of disease: multiple endocrine neoplasia type 1-relation to chromatin modifications and transcription regulation. Nature clinical practice. Endocr. Metab., 2, 562-570.
Mensah-Osman, E.J., Veniaminova, N.A. and Merchant, J.L. (2011) Menin and JunD regulate gastrin gene expression through proximal DNA elements. Am. J. Physiol. Gastrointest. Liver Physiol., 301, 783-790.
Wuescher, L., Angevine, K., Hinds, T., Ramakrishnan, S., Najjar, S.M. and Mensah-Osman, E.J. (2011) Insulin regulates menin expression, cytoplasmic localization, and interaction with FOXO1. American journal of physiology. Endocr. Metab., 301, 474-483.
Albert, I. and Jais, J.P. (2000) The use of frailty models in genetic studies: application to the relationship between end-stage renal failure and mutation type in Alport syndrome. European Community Alport Syndrome Concerted Action Group (ECASCA). J. Epidemiol. Biostat. 5, 169-175.
Storey, J.D. (2002) A direct approach for false discovery rates. J. R. Stat. Soc., 64, 479-488.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.